SillaJen

SillaJen completes Jennerex acquisition

Monday, March 17, 2014

SillaJen, a privately held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, has completed the acquisition of San Francisco-based Jennerex. Privately held Jennerex is a clinical-stage, biotherapeutics company developing best-in-class targeted oncolytic immunotherapies.

[Read More]

SillaJen to acquire Jennerex

Wednesday, November 27, 2013

SillaJen, a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, will acquire San Francisco-based Jennerex, a privately-held, clinical-stage biotechnology company developing best-in-class targeted oncolytic immunotherapies for solid tumors.

[Read More]